Group items tagged

Biosimilars, also known as biologic products, are currently the fastest growing category of medical products in the United States, with sales estimated at more than $40 billion dollars annually. When prescribed by doctors, these products may provide more effective treatment options for patients suffering from a chronic disease or condition. In late August, the FDA held a forum on biosimilars. The topic was "biosimilar medications - what are they, how do they work, and are they safe and effective." Representatives from the FDA, pharmaceutical companies, and biotechnology organizations attended the forum. The forum included individuals who are leading the charge to register biosimilar products for clinical trials. According to the FDA, the agency will begin accepting applications for biologic drugs in late fall of 2020. In Japan, various manufacturers are focused on developing pipelines that contain biosimilar candidates aimed at treating various therapeutic conditions for patients in Japan. For instance, in December 2020, Alvotech and Japanese pharmaceutical company Fuji Pharma agreed on an extension on their exclusive strategic partnership for the commercialization of four biosimilar medicines in Japan. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/biosimilars-and-impact-of-covid-19.html

Protein A colorimetric resins are the most extensively used affinity purifiers in bio-manufacturing and other industries. Protein A colorimetry is a robust, high-throughput chromatography method and is used primarily as a capture step because of its inherent precision. Approval and launch of new biosimilars is expected to propel growth of the protein A resin market. For instance, in December 2020, Sandoz Canada Inc., a generics and biosimilars manufacturer and a division of the Switzerland-based multinational Novartis AG, received Health Canada authorization for Hyrimoz (adalimumab injection, reference biologic drug: Humira) on November 4, 2020 for marketing in Canada. Hyrimoz, the new biosimilar, has been approved for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis. Moreover, high prevalence of chronic diseases is also expected to aid in growth of the protein A resin market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/emergence-of-covid-19-to-offer_23.html

Stomach cancer is a growth of abnormal tissues that form a tumor in the part of your abdomen. Symptoms of stomach cancer often include persistent abdominal pain, extreme heartburn, extreme vomiting, severe indigestion, abdominal swelling, and frequent diarrhea. These symptoms are common for all forms of stomach cancer but when cancer spreads to the upper part of the chest, the symptoms become far more severe and may eventually cause death. Stomach cancer has the highest survival rate of any type of cancer in the world. Crocetin (trade name Eulexin) is the first Stomach Cancer Drug that is used in the treatment of gastric cancer. It was later on approved for treating peritoneal mesothelioma but was not marketed extensively due to its negative outcomes at the beginning. The increasing prevalence of stomach cancer is expected to drive growth of the global stomach cancer drugs market during the forecast period. According to the American Cancer Society (ACS), in 2020, around 27,600 new cases of stomach cancer are expected to be diagnosed in the U.S. According to the World Cancer Research Fund, in 2018, over 1 million new cases of cancer were diagnosed across the globe. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/stomach-cancer-drugs-market-continues.html